What is BillionToOne, Inc.'s (BLLN) StockRank?

MoatMap's StockRank for BillionToOne, Inc. (BLLN) is 41/100, with a Hold signal. This is a composite score combining Quality (70), Value (9), and Momentum (55) factor ranks across MoatMap's 20,000+ stock universe.

Does BillionToOne, Inc. have an economic moat?

BillionToOne, Inc. (BLLN) has a Quality factor score of 70/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is BillionToOne, Inc. a buy, hold, or sell?

MoatMap's current signal for BillionToOne, Inc. (BLLN) is Hold, based on a StockRank of 41/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is BillionToOne, Inc. in?

BillionToOne, Inc. (BLLN) operates in the Healthcare sector, specifically the Diagnostics & Research industry (United States).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

BLLN

HOLD

BillionToOne, Inc. · Healthcare · United States · $5.8B · Avg Vol: $89M/d

StockRank

Get insider-trade alerts

P/E (TTM)

236.1x

ROE

8.7%

D/E

0.3x

Dividend %

—

COMPANY DESCRIPTION

BillionToOne, Inc. is a molecular diagnostics company leveraging its proprietary quantitative molecular counting technology to develop highly accurate non-invasive tests for prenatal conditions and early cancer detection. Its competitive advantage lies in its unique technology, which provides unprecedented resolution and sensitivity, enabling precise detection of genetic variations from small biological samples. The company is positioned to disrupt traditional genetic and oncology diagnostics with its innovative platform.

FINANCIAL SUMMARY (USD)

Year	2023	2024	2025	CAGR	TTM	2026E	2027E	Fwd CAGR
Revenue	—	—	305.1M	—	354.5M	454.1M	577.0M	37.5%
EPS	-2.10	-1.05	0.18	—	0.53	0.30	—	66.5%
Shares	44.7M	44.7M	45.8M	+2.4%	41.4M	—	—	—
Debt	—	—	108.9M	—	144.2M	—	—	—
Equity	—	—	480.1M	—	—	—	—	—
Op CF	—	—	24.6M	—	37.4M	—	—	—
Inv CF	—	—	-8.9M	—	—	—	—	—
Fin CF	—	—	288.8M	—	—	—	—	—

Loading 1Y...

PRICE (1Y)+26.6%

SMA 50SMA 200

$127.98

RSI (14)

60.8

SCORE BREAKDOWN

Quality

ROIC

1.3%48.2

ROE

8.7%69.1

GP/Assets

39.4%79.7

Op. Margin

16.5%78.1

FCF/Assets

2.6%58.3

Piotroski

497.4

Int. Cover

50.0x88.8

D/E Ratio

0.29x42.8

Current Ratio

10.92x88.0

Value

P/E (TTM)

236.1x4.1

EV/EBITDA

124.6x3.6

P/FCF

346.9x4.3

P/B

11.4x9.8

P/S

16.2x19.9

Div Yield

—N/A

Momentum

52W High %

—N/A

RS 6M

38%90.5

SMA 50/200

—N/A

EPS Rev 4W

0.0%62.5

EPS Rev 12W

+15.1%90.1

EPS Improve

+94%71.9

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$5.8B

P/E (Forward)

121.5x

Gross Margin

70.4%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of BLLN are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
BLLN	BillionToOne, Inc.(you)	$5.8B	41	HOLD
TWST	Twist Bioscience Corporation	$5.6B	45	HOLD
ADPT	Adaptive Biotechnologies Corporation	$3.6B	43	HOLD
RDNT	RadNet, Inc.	$4.8B	31	SELL
SHC	Sotera Health Company	$4.9B	66	BUY
NEO	NeoGenomics, Inc.	$1.8B	48	HOLD
GH	Guardant Health, Inc.	$19.5B	47	HOLD
GRAL	GRAIL, Inc.	$2.9B	21	SELL
RVTY	Revvity, Inc.	$12.3B	65	BUY
CRL	Charles River Laboratories International, Inc.	$10.9B	69	BUY

Peer medians: ROE -25.6% · P/E 27.6x · Gross margin 50.5%

BillionToOne, Inc. (BLLN) — Stock Score Summary

BillionToOne, Inc. (BLLN) has a MoatMap StockRank of 41/100 based on Quality (70/100), Value (9/100), and Momentum (55/100) factor scores. The current signal is HOLD.

Key Financial Metrics

Price	$127.98
Market Cap	$5.8B
P/E (TTM)	236.11
P/E (Forward)	121.50
Price/Book	11.38
Return on Equity	8.7%
Return on Invested Capital	1.3%
Debt/Equity	0.29x
Gross Margin	70.4%
Operating Margin	16.5%
Revenue Growth	83.8%
Free Cash Flow	$17M

BillionToOne, Inc. operates in the Diagnostics & Research industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is BillionToOne, Inc.’s (BLLN) StockRank?: MoatMap’s StockRank for BillionToOne, Inc. (BLLN) is 41/100, with a Hold signal. It is a composite of Quality (70), Value (9), and Momentum (55) factor ranks across MoatMap’s 20,000+ stock universe.
Does BillionToOne, Inc. have an economic moat?: BillionToOne, Inc. (BLLN) has a Quality factor score of 70/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is BillionToOne, Inc. a buy, hold, or sell?: MoatMap’s current signal for BillionToOne, Inc. (BLLN) is Hold, based on a StockRank of 41/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is BillionToOne, Inc. in?: BillionToOne, Inc. (BLLN) operates in the Healthcare sector, specifically the Diagnostics & Research industry (United States).